FDA granted Priority Review to Kyprolis (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. The agency also accepted the drug’s supplemental new drug application designed to support the conversion of accelerated approval to full approval and expand the current Kyprolis indication. FDA set a target action date of July 26.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
